An absolute bioavailability, safety and tolerability study of BMS-936557 following subcutaneous administration compared to intravenous administration in healthy subjects.

开始日期2012-08-08

申办/合作机构

Bristol Myers Squibb Co.

NCT01466374 / Completed临床2期

A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease

The purpose of this study is to determine whether BMS-936557 is effective for the treatment of moderate to severely active Crohn's Disease in patients who have had insufficient response and/or intolerance to conventional therapy for Crohn's Disease.

开始日期2011-12-01

申办/合作机构

Bristol Myers Squibb Co.

NCT01294410 / Completed临床2期

A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)

The purpose of this study is to determine whether BMS-936557 is effective in the treatment of moderate to severely active ulcerative colitis in patients who have had insufficient response and/or intolerance to other medical therapy for ulcerative colitis

开始日期2011-03-01

申办/合作机构

Bristol Myers Squibb Co.

100 项与 Eldelumab 相关的临床结果

登录后查看更多信息

100 项与 Eldelumab 相关的转化医学

登录后查看更多信息

100 项与 Eldelumab 相关的专利（医药）

登录后查看更多信息

项与 Eldelumab 相关的文献（医药）

2024-02-01·Cytokine

Production and characterization of anti-porcine CXCL10 monoclonal antibodies

Article

作者: Suresh, Raksha ; LaBresh, Joanna ; Renukaradhya, Gourapura J ; Lunney, Joan K ; Chick, Shannon ; Hailstock, Taylor ; Manirarora, Jean N ; Sullivan, Yvonne B ; Dai, Chaohui ; Walker, Kristen E ; Aquino, Jovan ; Patil, Veerupaxagouda

Research on C-X-C motif chemokine ligand 10 (CXCL10) has been widely reported for humans and select animal species, yet immune reagents are limited for pig chemokines. Our goal is to provide veterinary immunologists and the biomedical community with new commercial immune reagents and standardized assays. Recombinant porcine CXCL10 (rPoCXCL10) protein was produced by yeast expression and used to generate a panel of α CXCL10 monoclonal antibodies (mAbs). All mAbs were assessed for cross-inhibition and reactivity to orthologous yeast expressed CXCL10 proteins. Characterization of a panel of nine α PoCXCL10 mAbs identified six distinct antigenic determinants. A sensitive quantitative sandwich ELISA was developed with anti-PoCXCL10-1.6 and -1.9 mAb; reactivity was verified with both rPoCXCL10 and native PoCXCL10, detected in supernatants of peripheral blood mononuclear cells stimulated with rPoIFNγ or PMA/Ionomycin. Immunostaining of in vitro rPoIFNγ stimulated pig spleen and blood cells verified CXCL10 + cells as CD3-CD4-CD172+, with occasional CD3-CD4 + CD172 + subsets. Comparison studies determined that α PoCXCL10-1.4 mAb was the ideal mAb clone for intracellular staining, whereas with α PoCXCL10-1.1 and -1.2 mAbs were best for immunohistochemistry analyses. These techniques and tools will be useful for evaluating swine immune development, responses to infectious diseases and vaccines, as well as for improving utility of pigs as an important biomedical model.

2022-06-01·Tissue & cell4区 · 生物学

Anti-CXCL10 monoclonal antibody therapy protects against the diabetic retinopathy in the mouse model induced by streptozotocin

4区 · 生物学

Article

作者: Sun, Rui-Xue ; Li, Ya-Nan ; Li, Li ; Wang, Min ; Li, Fang ; Li, Yun-Fei ; Tang, Guang-Xian ; Sun, Zhao-Hui ; Yu, Hua

OBJECTIVE:

To explore the effect of CXC chemokine CXCL10 in the mice with diabetic retinopathy (DR).

METHODS:

DR models were constructed on mice via injection of streptozotocin (STZ). At 3 weeks of STZ, mice were treated with anti-CXCL10 monoclonal antibodies (mAb)/control mAb, and a series of experiments were then conducted at 6 weeks of STZ, including HE staining, western blotting, retinal trypsin digestion, real-time qPCR and enzyme-linked immuno sorbent assay (ELISA). The corresponding kits were used to detect the activity of oxidative stress markers.

RESULTS:

Compared with nondiabetic eyes, DR mice both at 3 and 6 weeks presented the decreases in the total retinal thickness, the retinal outer nuclear layer (ONL) thickness, and the cells of ganglion cell layer (GCL), with the upregulated CXCL10, pro-inflammatory cytokines and malondialdehyde (MDA), as well as the downregulated levels of superoxide dismutase (SOD), glutathione peroxidase (GPx) and CAT, especially in those at 6 weeks, which were attenuated by the anti-CXCL10 mAb treatment. Moreover, in comparison with the DR mice, mice in the DR + anti-CXCL10 mAb group gained the significant decrease in the number of acellular capillaries of retina, with up-regulations of Claudin-5 and ZO-1 and down-regulations of VEGF and FGF-2. The DR mice injected with anti-CXCL10 mAb demonstrated alleviated retinal pathology as compared to mice at 3 weeks of STZ.

CONCLUSION:

Anti-CXCL10 mAb could mitigate the retinal pathology of DR mice, with the decreased inflammation and oxidative stress, thus mediating a delay in the development or disease improvement in patients of DR.

2021-06-01·Translational research : the journal of laboratory and clinical medicine2区 · 医学

Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis

2区 · 医学

Article

作者: Hyun Jung Yoo ; Shin Eui Kang ; Yeong Wook Song ; Eun Bong Lee ; Jae Eun Park ; Jin Kyun Park ; Young Woo Park ; Bum Chan Park ; Eun Young Lee ; Heun soo Kang

This study was aimed at generating and investigating the efficacy of a novel monoclonal bispecific antibody (BsAb) for the combined inhibition of tumor necrosis factor-α (TNF-α) and CXCL10 as a treatment option for rheumatoid arthritis (RA). A novel BsAb targeting TNF-α and CXCL10 was generated by conjugating a single-chain variable fragment (scFv) of the anti-CXCL10 monoclonal antibody to the Fc region of adalimumab (ADA). The effects of the BsAb on the inflammatory response in the in vitro and in vivo development of arthritis and joint destruction were evaluated in human TNF transgenic (hTNF-Tg) mice, and K/BxN serum transfer arthritis models. The BsAb inhibited CXCL10-mediated CD8⁺ T cell migration. The binding affinity of the BsAb to TNF-α was comparable to that of ADA and suppressed TNF-α induced cell death and inhibited TNF-α induced ICAM-1 and VCAM-1 in RA fibroblast-like synoviocytes (FLSs). The BsAb decreased the expression of TNFSF11 and the production of IL-6 in RA-FLS cells stimulated with TNF-α and CXCL10. Treatment with the BsAb attenuated the development of arthritis in hTNF-Tg mice and suppressed LPS-induced bone erosion. In the K/BxN serum transfer model, BsAb effectively attenuated ankle swelling, synovial inflammation, cartilage damage, and bone destruction, reducing the activation of osteoclasts. The additional neutralization of TNF-α and CXCL10 from treatment with the novel BsAb was more effective than TNF-α inhibition alone in the in vitro and in vivo models of RA. Thus, the BsAb, targeting both TNF-α and CXCL10, may provide a new therapeutic opportunity for RA patients who fail to respond to the blockade of a single cytokine.

项与 Eldelumab 相关的新闻（医药）

2024-04-11

·BioSpace

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024 in Toronto, Ontario. Edesa's Chief Executive Officer Par Nijhawan, MD, is scheduled to present on Wednesday, April 17 at 11:00 am ET. To meet with Edesa management during the conference, please utilize the conference's online portal or contact the company directly at investors@edesabiotech.com. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Edesa is also planning to investigational new drug application for a future Phase 2 study of paridiprubart for pulmonary fibrosis. For its dermatology assets, the company has received regulatory approval to conduct a Phase 2 trial of its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. Sign up for news alerts. Connect with us on X (Twitter) and LinkedIn. Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements. CONTACT: Gary Koppenjan Edesa Biotech, Inc. (289) 800-9600 investors@edesabiotech.com SOURCE: Edesa Biotech View the original press release on accesswire.com

临床2期临床3期

2024-03-07

·BioSpace

Edesa Biotech to Participate in Barclays Global Healthcare Conference

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management will participate in the Barclays 26th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024. Attendees interested in meeting with Edesa can request meetings through conference organizers or by contacting the company at investors@edesabiotech.com. About Edesa Biotech Edesa Biotech, Inc. (Nasdaq:EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Edesa is also planning to investigational new drug application for a future Phase 2 study of paridiprubart for pulmonary fibrosis. For its dermatology assets, the company has received regulatory approval to conduct a Phase 2 trial of its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. Sign up for news alerts. Connect with us on X (Twitter) and LinkedIn. Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements. Contact: Gary Koppenjan Edesa Biotech, Inc. (289) 800-9600 investors@edesabiotech.com SOURCE: Edesa Biotech, Inc. View the original press release on accesswire.com

临床2期临床3期

2024-03-04

·BioSpace

Edesa Biotech to Participate in Upcoming Dermatology Meetings - March 04, 2024

TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company plans to participate in the American Contact Dermatitis Society Annual Meeting on March 7, 2024 and the American Academy of Dermatology Annual Meeting from March 8-12, 2024 in San Diego, California. Attendees interested in meeting with Edesa can request meetings by contacting the company at investors@edesabiotech.com. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Edesa is also planning to investigational new drug application for a future Phase 2 study of paridiprubart for pulmonary fibrosis. For its dermatology assets, the company has received regulatory approval to conduct a Phase 2 trial of its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. Sign up for news alerts. Connect with us on X (Twitter) and LinkedIn. Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements. Contact: Gary Koppenjan Edesa Biotech, Inc. (289) 800-9600 investors@edesabiotech.com SOURCE: Edesa Biotech, Inc. View the original press release on accesswire.com

临床2期临床3期

100 项与 Eldelumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10404	Eldelumab	-	DB06116

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
克罗恩病	临床2期	美国	Bristol Myers Squibb Co.	2011-12-01
克罗恩病	临床2期	比利时	Bristol Myers Squibb Co.	2011-12-01
克罗恩病	临床2期	法国	Bristol Myers Squibb Co.	2011-12-01
克罗恩病	临床2期	匈牙利	Bristol Myers Squibb Co.	2011-12-01
克罗恩病	临床2期	以色列	Bristol Myers Squibb Co.	2011-12-01
克罗恩病	临床2期	波兰	Bristol Myers Squibb Co.	2011-12-01
克罗恩病	临床2期	波多黎各	Bristol Myers Squibb Co.	2011-12-01
克罗恩病	临床2期	南非	Bristol Myers Squibb Co.	2011-12-01
溃疡性结肠炎	临床2期	美国	Bristol Myers Squibb Co.	2008-04-01
溃疡性结肠炎	临床2期	加拿大	Bristol Myers Squibb Co.	2008-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01466374 (Pubmed \| J Crohns Colitis)	临床2期	克罗恩病	121	Eldelumab 10 mg/kg	蓋鹹積觸網繭鹹鹽積鬱(鹹襯窪膚鬱醖積鏇繭壓) = 築鹹廠築製夢廠遞鹹壓醖醖鑰觸繭蓋遞淵製積 (願鑰製顧膚觸醖蓋觸觸 ) 更多	积极	2017-07-01
				Eldelumab 20 mg/kg	蓋鹹積觸網繭鹹鹽積鬱(鹹襯窪膚鬱醖積鏇繭壓) = 積觸鹽膚窪積夢構蓋鹹醖醖鑰觸繭蓋遞淵製積 (願鑰製顧膚觸醖蓋觸觸 ) 更多
EASD2014	N/A	1型糖尿病 CXCL10	-	Anti-CD3 monoclonal antibodies	遞簾憲膚範憲窪襯簾廠(鹹鹽齋製鏇繭選壓積願) = marked reduction of CD4 and CD8 T cells in the pancreas of mice treated with the CT compared to mono-therapies at day 31 after infection 願獵繭衊壓廠窪網製憲 (顧衊繭艱鏇艱繭範憲觸 ) 更多	积极	2014-09-19
				Anti-CXCL10 monoclonal antibody
NCT00656890 (Not provided, Pubmed \| Gut)	临床2期	溃疡性结肠炎	109	BMS-936557	衊衊壓顧鬱醖顧築網構(範夢憲遞構襯鏇憲齋鏇) = 鏇願蓋範糧選蓋夢膚鹹網鏇觸簾願觸製鏇襯窪 (醖獵襯醖夢鑰齋簾遞範 ) 更多	-	2014-03-01
				Placebo	衊衊壓顧鬱醖顧築網構(範夢憲遞構襯鏇憲齋鏇) = 壓廠願顧艱築鑰觸遞鏇網鏇觸簾願觸製鏇襯窪 (醖獵襯醖夢鑰齋簾遞範 ) 更多
NCT01017367 (Pubmed)	临床2期	类风湿关节炎	70	MDX-1100	鬱襯顧繭鏇繭遞廠廠衊(淵醖積觸齋鹹繭醖廠艱) = 選繭簾構鑰範衊構艱構壓衊窪鑰醖願艱糧鑰遞 (夢鏇選餘鏇窪艱築襯構 )	积极	2012-06-01
				Placebo	鬱襯顧繭鏇繭遞廠廠衊(淵醖積觸齋鹹繭醖廠艱) = 鬱鑰鬱憲鏇醖膚膚獵網壓衊窪鑰醖願艱糧鑰遞 (夢鏇選餘鏇窪艱築襯構 )